Table 2.
Association between loss of RASSF1A expression and clinicopathological factors.
| Factors | Total cases | Loss of RASSF1A expression | ||
|---|---|---|---|---|
| No. | No. (% of total) | χ2 | P | |
| Age | ||||
| <60 | 41 | 22 (53.66%) | 0.196 | 0.658 |
| ≥60 | 35 | 17 (48.57%) | ||
| Sex | ||||
| Male | 44 | 27 (61.36%) | 4.223 | 0.040 |
| Female | 32 | 12 (37.5%) | ||
| Site | ||||
| Colon | 38 | 24 (63.16%) | 4.266 | 0.039 |
| Rectum | 38 | 15 (39.47%) | ||
| Tumor size | ||||
| <5 cm | 55 | 31 (56.36%) | 2.030 | 0.154 |
| ≥5 cm | 21 | 8 (38.10%) | ||
| Differentiation grade | ||||
| Poor | 32 | 13 (40.63%) | 2.529 | 0.112 |
| Moderate-well | 44 | 26 (59.09%) | ||
| Invasion depth | ||||
| T1 + T2 | 17 | 11 (64.71%) | 1.572 | 0.210 |
| T3 + T4 | 59 | 28 (47.58%) | ||
| Tumor stage | ||||
| I/II/III | 56 | 28 (50%) | 0.114 | 0.736 |
| IV | 20 | 11 (55%) | ||
Bold values represent P values which are considered to be statistically significant at <0.05.